{"ok":true,"nota":{"id":"97606e241c5488b1","slug":"casi-6-de-cada-100-pacientes-con-leucemia-no-logran-recuperar-sus-defe-97606e","titulo":"Casi 6 de cada 100 pacientes con leucemia no logran recuperar sus defensas tras un trasplante de médula","resumen":"Un estudio europeo analizó a casi 2.500 pacientes con leucemia mieloide aguda que recibieron un trasplante de médula de donante no emparentado con un tratamiento de ciclofosfamida después del trasplante. Midieron cuántos no lograron recuperar sus glóbulos blancos en el primer mes y qué pasó después con ellos.","fuente":"zenodo","fuenteNombre":"Zenodo · Investigación abierta","color":"#1682d4","autor":"Nagler A, Galimard JE, Kayser S","url":"https://doi.org/10.1038/s41409-025-02726-8","imagen":"/hoy/portada/97606e241c5488b1","tema":"salud","subtemas":["trasplante de médula","leucemia mieloide aguda","recuperación de defensas","donante no emparentado","ciclofosfamida"],"entidades":["EBMT","ALWP"],"formato":"dato","entretenimiento":false,"pubTs":"2026-10-19T06:49:49.000Z","indexTs":"2026-10-21T10:34:42.643Z","hash":"b6c567d89f7d3d993ec2dbf321cf17686a07361ea9a6d689a15297b63cd4eefb","tsa":{"time":"Oct 21 10:35:56 2026 GMT","provider":"freetsa.org","sobre":"sello"},"stats":{"views":0,"likes":0,"clicks":0,"dwell":0},"tipo":"normal","registro":"hallazgo","porQueImporta":"Para un paciente de acá que espera un trasplante, la diferencia entre sobrevivir y no hacerlo se juega en semanas de vigilancia intensa. Casi el 93% de los pacientes recuperó sus defensas en el primer mes, pero el 1,8% murió sin recuperarlas. Quien pasa por esto necesita un equipo que esté atento a los primeros días, porque ahí se define mucho.","quienFirma":"Grupo ALWP/EBMT (Sociedad Europea de Trasplante de Médula Ósea)","confianza":"revisado","consulta":null},"sello":{"hash":"b6c567d89f7d3d993ec2dbf321cf17686a07361ea9a6d689a15297b63cd4eefb","sello":"0844fddac0a928cc73a3c17b6ff057a4936bde9ae9ac8b8d0e74c592f591c7f7","beacon":{"drand":{"cadena":"8990e7a9aaed2ffed73dbd7092123d6f289930540d7651336225dc172e51b2ce","ronda":6571597,"aleatorio":"457f4f4cf22f0e6c2e9758e5b211ac56883c24c6e8c5e375baf6537d39797215","tiempo":"2026-10-21T10:35:30.000Z"},"nist":{"cadena":2,"pulso":1993004,"salida":"23161ED84C8333D8735666F0B82E202695897452E701B068B63EF76A2E59D22F1B819FE2CF27AC06B5894483118E32D36F4246E7C1D82B4789A57D7588B065D3","tiempo":"2026-10-21T10:35:00.000Z"},"noAntes":"2026-10-21T10:35:30.000Z"},"verificacion":{"drand":true,"nist":true},"tsa":{"time":"Oct 21 10:35:56 2026 GMT","provider":"freetsa.org","sobre":"sello"},"original":{"titulo":"Outcomes of primary graft failure in acute myeloid leukemia patients following unrelated transplantation with post-transplant cyclophosphamide: a study from the ALWP/EBMT.","descripcion":"We assessed pGF in 2497 AML patients undergoing HSCT from 8-10/10 HLA-matched UD with PTCy. pGF was defined as failure to achieve an ANC = 0.5 × 10(9)/L by day +30 after HSCT. The day +30 cumulative incidence of ANC was 92.6% (95%CI: 91.5-93.6), and the incidence of death without ANC recovery was 1.8% (95% CI: 1.3%-2.3%), corresponding to 141 (5.6%) patients not achieving an ANC = 0.5 × 10(9)/L by day +30. PB was the graft source in 89.4% of the patients, and 56% received reduced-intensity conditioning. 21 patients underwent a second HSCT (15 in the absence of ANC recovery and 6 after ANC recovery). 1-y NRM and RI post-pGF were 22.1% and 22.4%, respectively. 1-y LFS and OS post-pGF were 59% and 55.5%, respectively. ANC recovery evaluated as a time-dependent covariate, KPS = 90, and being in CR at the time of HSCT were associated with improved OS. In conclusion, the incidence of pGF post-","pubDate":"2026-10-19T06:49:49Z","url":"https://doi.org/10.1038/s41409-025-02726-8"},"indexado":"2026-10-21T10:34:42.643Z"}}